Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Chengdu Chipscreen Pharmaceutical Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, indicating a broad spread of examination relative to the total volume of pending applications. The presence of 2 distinct art units suggests that the company's intellectual property may span different specialized sub-sectors within the broader biotechnology field, requiring a strategy that accounts for varying examination standards across these administrative groups.
LU, CHENG is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. Because this examiner is responsible for 1 of the 2 total pending actions, their individual examination style and historical trends will significantly influence the overall progression of the portfolio. The fact that each of the 2 distinct examiners is handling a single matter suggests a lack of examiner concentration, which may prevent the applicant from leveraging consistent feedback from a single individual across multiple applications.
Practitioners should note that the pending office actions are isolated in different administrative environments. With 2 distinct art units involved, the prosecution team must prepare for potentially divergent prior art citations and legal interpretations. Monitoring the specific tendencies of LU, CHENG will be crucial, as this examiner represents a significant portion of the current workload for Chengdu Chipscreen Pharmaceutical Ltd.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, CHENG | 1 | 54.1% | +64.1% |
| HIBSHMAN, SARAH GRACE | 1 | 38.9% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025322 | USE OF CHIAURANIB IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN ANTITUMOR THERAPY | LU, CHENG | 22d overdue |
| 17922133 | DRUG COMBINATION FOR TREATING DIABETES MELLITUS AND COMPLICATIONS THEREOF AND PHARMACEUTICAL COMPOSITION OF DRUG COMBINATION | HIBSHMAN, SARAH GRACE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18025322 | USE OF CHIAURANIB IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN ANTITUMOR THERAPY | LU, CHENG | 1642 | §103Other | Non-Final OA | 22d overdue | Pending | Mar 08, 2023 |
| 17922133 | DRUG COMBINATION FOR TREATING DIABETES MELLITUS AND COMPLICATIONS THEREOF AND PHARMACEUTICAL COMPOSITION OF DRUG COMBINATION | HIBSHMAN, SARAH GRACE | 1693 | §103 | Non-Final OA | — | Pending | Oct 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial